Tuzepat 440 mg (Trastuzumab)

Adult administration

For the treatment of metastatic breast cancer, it can be divided into weekly and tri-weekly regimens. Weekly regimen: Initial loading dose 4 mg/kg, followed by a maintenance dose of 2 mg/kg every week (starting one week after the initial loading dose). Tri-weekly regimen: Initial loading dose 8 mg/kg, followed by a maintenance dose of 6 mg/kg every 3 weeks (starting three weeks after the initial loading dose). When combined with docetaxel or paclitaxel, initial administration.

This medication may affect heart function, so patients with heart disease or those who have received heart treatment in the past must undergo cardiac examination before administration. Careful attention is especially required for patients at high risk of heart failure or the elderly. Furthermore, allergic reactions or infusion-related side effects may occur during administration, so the patient's condition should be closely monitored during administration. It is safe not to administer this medication to patients who have severe respiratory symptoms or significant pulmonary abnormalities. This medication should not be used in newborns or premature infants as the preservative ingredients in this formulation may pose a risk. Women who are pregnant or of childbearing potential should ensure effective contraception during and after the use of this medication, considering its potential impact on the fetus. The safety and efficacy of this medication in children have not been established; therefore, it is not recommended for patients under 18 years of age. Dizziness or drowsiness may occur during administration, so driving or operating machinery should be avoided. The dosing solution should be prepared under sterile conditions, and the specified storage and usage conditions must be strictly adhered to. There have been no significant reports of drug interactions when this medication is combined with other drugs; however, monitoring of cardiac function is necessary during combination therapy with chemotherapeutics.

Serious side effects

• Rash
• angioedema
• breathing difficulty
• wheezing
• anaphylaxis
• hypotension
• bronchospasm
• ventricular tachycardia
• decreased oxygen saturation
• respiratory distress syndrome

Mild side effects

• Fever
• nausea
• vomiting
• headache
• chills
• loss of appetite
• insomnia
• anxiety
• depression
• dizziness

This medication should be stored in a sealed container to prevent air and moisture from entering, and to maintain freshness and effectiveness, it should be kept at a refrigerated temperature between 2 to 8 degrees Celsius. Therefore, always keep the lid tightly closed until it is used, and avoid extremely hot or cold environments.

Appearance

A colorless injectable solution in a vial filled with a freeze-dried white to pale yellow substance, which becomes a clear or slightly cloudy liquid that is colorless to light yellow when a solvent is added.

Package unit

1 vial/box [vial (892.7 mg)]